Autolus Therapeutics Ltd (AUTL) Company Information

About this company

Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Key people

Michael W. Bonney

Chairman of the Board

Christian Martin Itin

Chief Executive Officer, Executive Director

Martin Pule

Founder, Senior Vice President, Chief Scientific Officer

Robert Dolski

Chief Financial Officer, Senior Vice President

Christopher Vann

Chief Operating Officer, Senior Vice President

Alexander Swan

Chief Human Resources Officer, Senior Vice President

Matthias Will

Executive Vice President, Chief Development Officer

Alex Driggs

Senior Vice President, Legal Affairs and General Counsel

David Brochu

Senior Vice President, Chief Technical Officer

Miranda Neville

Senior Vice President, Chief Project Officer

Robert W. Azelby